mCRPC Clinical Program

Turning the Tide

on Zytiga®-Resistant Metastatic
Castration-Resistant Prostate Cancer (mCRPC)

Adding Onvansertib to Daily Zytiga is Increasing the Duration of Response to Treatment and Progression-Free Survival

New Therapeutic Options are Needed to Overcome Resistance to SOC Androgen Receptor Signaling Inhibitors (ARSi)

Resistance develops to treatment with standard of care ARSi’s within 9-15 months.

ARSi’s offer a median overall survival (mOS) benefit of only ~4 months.

No effective treatment options are available for the up to 40% of mCRPC patients with an AR-V7 mutation.

Limited options for patients once resistant to abiraterone

New treatment options are needed to extend the duration of response to ARSi’s and increase overall survival.

Onvansertib + Abiraterone (Zytiga®)
Demonstrate Synergy in Abi-Resistant Model

Onvansertib + Abiraterone (Zytiga®)
Significantly Increases Apoptotic Cell Death¹

Why onvansertib is a promising option for
mCPRC: Overcoming resistance to Zytiga

Onvansertib in combination with Zytiga (abiraterone) demonstrates synergy in 
mCRPC and significantly increases the arrest of tumor cell division.

Assessment of Preliminary Efficacy and Duration of Response

Two-fold increase in disease control achieved with greater dose-density schedule in Arm C

Treatment Response and Duration

26% (5/19) DCR at 12 weeks in patients with at least 1 AR alteration
associated with abiraterone resistance

Onvansertib in Combination with FOLFIRI/Avastin® is Demonstrating Safety and Efficacy in KRAS-Mutated Metastatic Colorectal Cancer

Phase 2 multi-center open-label clinical trial NCT03414034

“This data shows that adding onvansertib to abiraterone in metastatic castration-resistant prostate cancer patients with an early resistance to abiraterone validates pre-clinical studies and shows potential as a new therapeutic option.”

Dr. David Einstein,
principal investigator at the
Beth Israel Deaconess Medical Center

Our Clinical Programs

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Leveraging the synergy of onvansertib to increase duration and response of overall survival.

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.